[go: up one dir, main page]

EP0652775B1 - Ciblage de liposomes sur la barriere hemato-encephalique - Google Patents

Ciblage de liposomes sur la barriere hemato-encephalique Download PDF

Info

Publication number
EP0652775B1
EP0652775B1 EP93917326A EP93917326A EP0652775B1 EP 0652775 B1 EP0652775 B1 EP 0652775B1 EP 93917326 A EP93917326 A EP 93917326A EP 93917326 A EP93917326 A EP 93917326A EP 0652775 B1 EP0652775 B1 EP 0652775B1
Authority
EP
European Patent Office
Prior art keywords
receptor
brain
composition
antibody
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP93917326A
Other languages
German (de)
English (en)
Other versions
EP0652775A1 (fr
Inventor
Michael J. Micklus
Nigel H. Greig
Stanley I. Rapoport
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of EP0652775A1 publication Critical patent/EP0652775A1/fr
Application granted granted Critical
Publication of EP0652775B1 publication Critical patent/EP0652775B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody

Definitions

  • This invention relates generally to the delivery of drugs into the brain by transcytosis across the blood-brain barrier. More particularly, the invention relates to the targeting of drug-containing liposomes to the blood-brain barrier by means of antibodies and binding fragments thereof which bind to receptors on capillary endothelial cells of the brain.
  • the barrier is due in part to tight intercellular junctions between brain capillary endothelial cells and prevents the passive movement of many substances from the blood to the brain.
  • the brain endothelial cells lack continuous gaps or channels connecting the luminal and abluminal membranes which would otherwise allow the passage of blood-borne molecules into the brain tissue. Instead, the presence of specific transport systems within the capillary endothelial cells, such as those for insulin, amino acids, glucose and transferrin, assure the controlled transport of compounds necessary to the functioning of the brain.
  • an intraventricular catheter is surgically implanted to deliver a drug directly into the brain. Not only does this involve an invasive procedure that itself is potentially harmful to the patient, but the drug delivered by this means is only superficially distributed within the brain.
  • the use of insulin as a vector to the blood-brain barrier may be limited by hypoglycemia side effects and by rapid clearance of the peptide by the liver, and transferrin may be limited as a vector by its high concentration in the plasma.
  • Friden et al., Proc. Natl. Acad. Sci. USA 88:4771-4775 (1991) have suggested that drugs conjugated to anti-transferrin receptor antibodies cross the blood-brain barrier.
  • liposomes can enhance drug delivery to the brain across the blood-brain barrier. See, e.g., Umezawa and Eto, Biochem. Biophys. Res. Comm. 153:1038-1044 (1988); Chan et al., Ann. Neurol. 21:540-547 (1987): Laham et al., Life Sciences 40:2011-2016 (1987); and Yagi et al., J. Appl. Biochem. 4:121-125 (1982).
  • Liposomes are small vesicles (usually submicron-sized) comprised of one or more concentric bilayers of phospholipids separated by aqueous compartments.
  • liposomes have been reported to enhance the uptake of certain drugs into the brain after intravenous injection (Chan et al., and Laham et al., ibid. ), it has more recently been shown that liposomes do not cross the blood-brain barrier. Schackert et al., Select. Cancer Therapeut. 5:73-79 (1989) and Micklus et al., Biochim. Biophys. Acta 1124:7-12 (1992). As noted in Micklus et al., ibid. , liposomes circulating in the plasma are ultimately taken up by the liver, digested and the lipid components released and redistributed to other organs. See also, Derksen et al., Biochim.
  • the present invention provides immunoliposomes and pharmaceutical compositions thereof capable of targeting pharmacological compounds to the brain.
  • Liposomes are coupled to an antibody binding fragment such as Fab, F(ab') 2 , Fab' or a single antibody chain polypeptide which binds to a receptor molecule present on the vascular endothelial cells of the mammalian blood-brain barrier.
  • the antibody binding fragment is prepared from a monoclonal antibody.
  • the receptor is preferably of the brain peptide transport system, such as the transferrin receptor, insulin receptor, IGF-I or IGF-2 receptor.
  • the antibody binding fragment is preferably coupled by a covalent bond to the liposome.
  • Pharmacological compounds which especially benefit from this invention are those which are typically poorly transported across the blood-brain barrier, such as hydrophilic peptides, and which are often highly potent in small quantities in the brain. These include, for example, peptide neurotrophic factors, neurotransmitters and neuromodulators, e.g., beta-endorphins and enkephalins.
  • the diameter of the liposome is less than 1 micron and typically smaller than about 0.45 microns.
  • a liposome containing the pharmacological compound is coupled to an antibody binding fragment which binds to a receptor molecule present on vascular endothelial cells of the mammalian blood-brain barriers, such as the transferrin receptor, insulin receptor, IGF-I or IGF-2 receptor.
  • the pharmaceutical-containing immunoliposome is then administered to the subject in an amount sufficient to effectively treat or prevent the disorder.
  • the preparation is usually administered parenterally, e.g., intravenously or intraarterially.
  • compositions for targeting drugs to and across the blood-brain barrier are comprised of a liposome, a pharmaceutical agent intended to be transported to the brain, and an antibody binding fragment which binds to a receptor present on vascular endothelium cells of the brain.
  • the receptor is transferrin receptor and the antibody which binds to the receptor is a binding fragment which lacks some or all of the Fc portion of the molecule to minimize clearance of the composition by the reticuloendothelial system (RES).
  • RES reticuloendothelial system
  • Liposomes are used in the present invention to carry the pharmaceutical agent of interest to the blood-brain barrier for ultimate transport across the barrier and into the brain.
  • liposomes include any synthetic (i.e., not naturally occurring) structure composed of lipid bilayers that enclose a volume. Liposomes include emulsions, foams, micelles, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like.
  • the pharmaceutical agent to be delivered across the blood-brain barrier is incorporated as part of a liposome in conjunction with the targeting molecule.
  • the receptor to which the antibody fragment/liposome is directed may be one or several receptors present in vascular endothelium of the brain.
  • the receptor should be sufficiently accessible to be bound by the antibody fragment coupled to the liposome.
  • Receptors which are present in higher quantities in the brain capillaries than others are preferred for enhancing levels of transport across the blood-brain barrier.
  • Receptors which may be targeted include, for example, transferrin receptor, insulin receptor, insulin-like growth factors I and II (IGF-I and IGF-II) receptors and other receptors of the brain peptide transport system, as generally described in Pardridge, Peptide Drug Delivery to the Brain, Raven Press, New York, NY (1991), and U.S. Patent 4,801,575, the glucose transport receptor and the like.
  • the receptor targeted by antibody binding fragment is transferrin receptor.
  • Transferrin receptor is selectively enriched on the endothelium of the brain microvascular endothelium of a variety of mammals, including humans, and is the primary pathway for iron to enter the brain. Iron-loaded transferrin, an 80 Kd glycoprotein, the principal iron transport protein in the circulation, undergoes transcytosis through the blood-brain barrier via the transferrin receptor. The structure and function of the transferrin receptor have been described in Seligman, Prog. Hematol. 13:131-147 (1983), which is incorporated by reference herein. Transferrin receptor is believed to project largely into the extracellular space. It can be isolated and purified from brain tissue using well known procedures. The purification, cloning, expression of human insulin receptor and the production of monoclonal antibodies thereto are described in U.S. Patent No. 4,761,371.
  • the targeted receptor purified from brain or expressed by recombinant DNA techniques may be used to produce antibodies, and preferably monoclonal antibodies, which may then be used to produce the antibody fragments useful in the present invention.
  • the antibodies are made to the receptor molecule or a portion of the receptor molecule, such as that domain or domains which contributes to ligand binding.
  • the antibody will bind to an extracellular portion of the receptor which is proximate to the binding site of the receptor's native ligand, e.g., transferrin or insulin.
  • the antibody does not substantially block or compete with the binding of ligand to the receptor.
  • Monoclonal antibodies to the human insulin receptor have also been reported, including cell lines available from the ATCC, such as ATCC HB175 ( J. Biol. Chem. 258:6561-6566 (1983)) and ATCC CRL 1827 ( Curr. Top. Cell. Reg. 27:83-94 (1985)).
  • Methods for the production of monoclonal antibodies are well known and may be accomplished by, for example, immunizing the animal with cells which express the receptor, substantially purified receptor, or fragments thereof as discussed above.
  • Antibody producing cells obtained from immunized animals are immortalized and screened, or screened first for the production of antibody which binds to the receptor protein and then immortalized.
  • an antibody fragment used in the present invention will generally lack the immunogenic Fc portion, the necessity of using human monoclonal antibodies is substantially avoided.
  • Such methods are generally known in the art and are described in, for example, EPO publications 173,494 and 239,400, which are incorporated herein by reference.
  • the production of single polypeptide chain binding molecules, also referred to as single chain antibodies, by recombinant DNA techniques is described in detail in U.S. Patent No. 4,946,778.
  • the antibody to the brain receptor molecule may be used intact or, more preferably, as a binding fragment thereof.
  • binding fragment is meant that the fragment retains an ability to specifically bind to an epitope of the target molecule of interest, such as transferrin or insulin receptor, for example.
  • Antibody binding fragments include at least the hypervariable or complementarity determining region (CDR) situated in an appropriate framework to produce a conformation which binds to the antigenic determinant. These binding fragments include, but are not limited to, Fv, Fab, F(ab') 2 , Fab', and single polypeptide chain binding molecules.
  • Antibody binding fragments can be produced from intact antibody molecules by a variety of procedures well known to those of skill in the art. For example, antibodies are usually fragmented by partial digestion with papain to produce two Fab fragments. Pepsin treatment can be used to produce the F(ab') 2 fragments where the two antigen binding domains are still bound together, i.e., as a multivalent binding molecule. Further reduction of the F(ab') 2 fragment with, e.g., dithiothreitol can be used to separate the antigen binding domains and produce two F(ab') fragments.
  • Pepsin treatment can be used to produce the F(ab') 2 fragments where the two antigen binding domains are still bound together, i.e., as a multivalent binding molecule.
  • Further reduction of the F(ab') 2 fragment with, e.g., dithiothreitol can be used to separate the antigen binding domains and produce two F(ab') fragments.
  • the preparation of the various antibody fragments is described in detail in, e.g., Harlow and Lane, Antibodies, A Laboratory Manual , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1988 pp. 626-631, and Parham, in Cellular Immunology , 4th ed., (ed. D.M. Weir), vol. 1, chap. 14, Blackwell Scientific Publ., CA 1986.
  • the polypeptide chains of the desired fragments may also be produced by a variety of recombinant DNA techniques and assembled intra- or extracellularly.
  • Liposomes for use in the invention may be formed from standard vesicle-forming lipids, which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally guided by consideration of, e.g., liposome size and stability in the bloodstream.
  • the lipids which can be employed in the present invention include, e.g., cholesterol hemisuccinate and salts thereof, tocopherol hemisuccinate and salts thereof, a glycolipid, a phospholipid such as phosphatidylcholine, phosphatidylethanolamine (PE), phosphatidylserine, phosphatidylglycerol, phosphatidic acid, phosphatidylinositiol, sphingomyelin, and the like, alone or in combination.
  • the phospholipids can be synthetic or derived from natural sources such as egg or soy.
  • Phosphatidylcholines having a variety of acyl chain groups of varying chain length and degree of saturation are available or may be isolated or synthesized by well known techniques. In general, less saturated phosphatidylcholines are more easily sized, particularly when the liposomes are sized below about 0.3 microns.
  • the acyl chain compositions of phospholipid may also affect the stability of liposomes in the blood. Sterols such as cholesterol can be combined with the phospholipids.
  • the phospholipids employed and the amount of sterol present depends on a number of factors such as lipophilicity of any added pharmaceutical agent, the targeting antibody fragment, and required properties of the liposome. These factors are generally known to those skilled in the art.
  • liposomes suitable for targeting to the blood-brain barrier in the present invention are available. See, for example, Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), Liposome Technology , ed. G. Gregoriadis, CRC Press, Inc., Boca Raton, FL (1984), U.S. Patent Nos. 4,235,871, 4,501,728, 4,837,028 4,957,735 and 5,019,369. Since the targeted liposomes of the invention are not intended for uptake by the reticuloendothelial system, the lipid components are further selected to increase time in the bloodstream.
  • the liposomes may be sized to achieve a desired size range and relatively narrow distribution of liposome sizes.
  • liposomes For delivery to the brain, liposomes should generally be less than about 1.0 microns in size, more preferably about 0.2 to 0.45 microns, which allows the liposome suspension to be sterilized by filtration.
  • a liposome suspension may be sonicated either by bath or probe down to small vesicles of less than about 0.05 microns in size. Homogenization may also be used, which relies on shearing energy to fragment large liposomes into smaller ones. Homogenizers which may be conveniently used include microfluidizers produced by Microfluidics of Boston, MA.
  • liposomes are recirculated through a standard emulsion homogenizer until selected liposomes sizes, typically between 0.1 and 0.5 microns, are observed.
  • selected liposomes sizes typically between 0.1 and 0.5 microns.
  • Extrusion of liposomes through a small-pore polycarbonate membrane or an asymmetric ceramic membrane is an effective method for reducing liposome sizes to a relatively well defined size distribution.
  • the suspension is cycled through the membrane one or more times until the desired liposome size distribution is achieved.
  • the liposomes may be extruded through successively smaller pore membranes to achieve a gradual reduction in liposome size.
  • Methods for coupling antibodies to liposomes generally involve either covalent crosslinking between a liposomal lipid and a native or modified antibody (or binding fragment thereof).
  • an antibody which has been covalently derivatized with a hydrophobic anchor, such as a fatty acid is incorporated into a preformed lipid.
  • a variety of crosslinking agents can be employed to produce a covalent link between a lipid and the antibody.
  • One protocol involves the derivatization of the free amino group of a PE with an amino reactive bifunctional crosslinker.
  • the derivatized PE along with other lipids are then used to form liposomes by the methods described above. Once incorporated into the liposomes the derivatized PE can be reacted with the antibody by using the second reactive site on the crosslinking reagent.
  • the use of heterobifunctional reagents are particularly useful because homocoupling between liposomes or between antibodies is avoided.
  • Heterobifunctional crosslinkers which can be used include N-hydroxysuccinimidyl 3-(2-pyridythio) propionate (SPDP), m-maleimidobenzoyl-N-hydroxysuccinimde (MBS) and the like, and homobifunctional crosslinkers include toluene-2,4-diisocyanate (TDIC) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI)).
  • TDIC toluene-2,4-diisocyanate
  • EDCI 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
  • Chemical crosslinking techniques also include the use of glutaraldehyde. These and other regents are reviewed in Connor and Huang, Pharmac. Ther. 28:341-365 (1985).
  • the covalent attachment of antibody fragments to liposomes by crosslinking provides the advantage of attaching a large amount of antibody binding fragment to the liposome surface, with little or no loss of entrapped aqueous content using these methods. Care should be taken, however, that the crosslinking conditions are not so harsh that antibody binding is adversely affected, or that the liposomes and their contents are damaged. To avoid the orientation of antibody molecules which may render them incapable of binding to antigen, a spacer arm between the antibody and the lipid may optionally be employed.
  • a non-crosslinking association of antibodies or binding fragments thereof with liposomes can also be employed.
  • This approach allows more than one type of antibody binding specificity per liposome, e.g., antibodies or fragments to different antigenic determinants on the transferrin molecule or even antibodies which bind to different receptors.
  • the flexibility of the molecule minimizes steric hindrance which may block binding of the antibody to the antigen.
  • the reagents involved in the non-covalent methods are relatively mild and do not come into direct contact with the contents of the liposomes, thus avoiding possible damage to the liposome components.
  • the non-covalent association of the antibody or fragment with the liposome can be accomplished by derivatizing the antibody component with a hydrophobic group.
  • the derivatized antibody is then incorporated into the vesicles by inserting the hydrophobic anchor into the bilayer.
  • Methods of derivatization include reacting the antibody with the N-hydroxysuccinimide ester of palmitic acid (NHSP) in the presence of 1-2% detergent, typically deoxycholate, as described in Huang et al., Biochem. Biophys. Acta 716:140-150 (1982).
  • NHSP N-hydroxysuccinimide ester of palmitic acid
  • palmitic acid chloranhydride can replace NHSP as the acylation reagent.
  • Another method to acylate the antibody involves derivatizing the head group of a PE or similar molecule rendering it capable of reacting with a sulfhydryl group.
  • the antibody's disulfide bonds are then reduced with dithiothreitol (DTT) and then incubated with the derivatized PE.
  • DTT dithiothreitol
  • a free PE or similar molecule is crosslinked to the carboxylic groups of an antibody by carbodiimide as described in Jansons and Mallett, Analyt. Biochem. 11:54-59 (1981), protecting the free amino groups of the antibody prior to the crosslinking to prevent homocoupling between antibody molecules.
  • the antibody or binding fragment thereof can become associated into the liposomes by a variety of established protocols.
  • the derivatized antibody is mixed with the liposome in the presence of detergent, and the detergent then removed by dialysis to form the immunoliposomes.
  • the preparation of immunoliposomes is also described in U.S. Patent No. 4,957,735.
  • the antibody or binding fragment thereof is attached to the liposome component after the liposome is prepared.
  • liposomes as drug delivery vehicles are extensively reviewed in Gregoriadis, (ed.), Liposomes as Drug Carriers: Recent Trends and Progress, John Wiley & Sons, NY (1988).
  • Therapeutic agents which may be delivered include protein neurotrophic factors, e.g., nerve growth factor, to treat brain injury and degenerative diseases, enzymes to replace those lost through genetic defects causing metabolic storage diseases, e.g., Tay-Sachs disease, neurotransmitters and neuromodulators, e.g., dopamine and beta-endorphin for treating Parkinson's disease, conditions associated with pain, disorders of movement or cognition and behavior, antibiotics, chemotherapeutic agents, diagnostic imaging agents, etc.
  • Particularly useful in the present invention are drugs such as peptides which have specific effects in the brain but which poorly cross into the brain normally, and have no or little effect in other organs.
  • One general class of drugs include water-soluble, liposome-permeable compounds which are characterized by a tendency to partition preferentially into the aqueous compartments of the liposome suspension, and to equilibrate, over time, between the inner liposomal spaces and outer bulk phase of the suspension.
  • Representative drugs in this class include propranolol, ibuprofin, gentamicin, tobramycin, penicillin, theophylline, bleomycin, etoposide, n-acetyl cysteine, verapamil, vitamins, and radio-opaque and particle-emitter agents, such as chelated metals.
  • the liposome composition may be stored in lyophilized form, with rehydration shortly before administration.
  • the composition may be prepared in concentrated form, and diluted shortly before administration.
  • a second general class of drugs are those which are water-soluble, but liposome-impermeable.
  • these are peptide or protein molecules, such as peptide hormones, enzymes, enzyme inhibitors, apolipoproteins, and higher molecular weight carbohydrates characterized by long-term stability of encapsulation.
  • Representative compounds in this class include nerve growth factor, interferon ( ⁇ , ⁇ or ⁇ ), oxytocin, vasopressin, insulin, interleukins (e.g., IL-1, IL-2, etc.), superoxide dismutase, tumor necrosis factor, somatostatin, thyrotropin releasing hormone, and macrophage colony stimulating factor, among others.
  • Peptide molecules and hormones which are typically very potent, and thus even small amounts crossing the blood-brain barrier can affect function, are particularly useful in targeted methods and compositions of the present invention. They include, for example, the ⁇ -endorphins and analogues, the enkephalins (relatively lipid soluble) such as Leu- and Met-enkephalins and analogues, melanocyte-stimulating hormone and melanocyte-stimulating hormone inhibitory factor, ⁇ -casomorphin, glucagon, delta sleep-inducing peptide and others, some of which are discussed in Banks and Kastin, supra ,
  • a third class of drugs are lipophilic molecules which tend to partition into the lipid bilayer phase of the liposome, and which are therefore associated with the liposomes predominantly in a membrane-entrapped form.
  • the drugs in this class are defined by an oil/water partition coefficient, as measured in a standard oil/water mixture such as octanol/water, of greater than 1 and preferably greater than about 5.
  • Representative drugs include prostaglandins, amphotericin B, methotrexate, cis-platin and derivatives, vincristine, vinblastine, progesterone, testosterone, estradlol, doxorubicin, epirubicin, beclomethasone and esters, vitamin E, cortisone, dexamethasone and esters, betamethasone valerete and other steroids, etc.
  • compositions for parenteral administration targeted for the blood-brain barrier which comprise a solution of a selected pharmaceutical contained in liposome associated with an antibody molecule or binding fragment thereof which binds to a brain receptor molecule, preferably the transferrin receptor molecule, dissolved in a pharmaceutically acceptable carrier, preferably an aqueous carrier.
  • aqueous carriers may be used, e.g., water, buffered water, 0.4% saline, 0.3% glycine, and the like, including glycoproteins for enhanced stability, such as albumin, lipoprotein, globulin, etc.
  • glycoproteins for enhanced stability such as albumin, lipoprotein, globulin, etc.
  • These compositions may be sterilized techniques referred to above or produced under sterile conditions.
  • the resulting aqueous solutions may be packaged for use or filtered under aseptic conditions and lyophilized, the lyophilized preparation being combined with a sterile aqueous solution prior to administration.
  • compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such an pH adjusting and buffering agents, tonicity adjusting agents and the like, for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
  • auxiliary substances such as sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, etc.
  • the concentration of the liposomes in these formulations can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily by fluid volumes, viscosities, etc., in accordance with the particular mode of administration selected.
  • Actual methods for preparing parenterally administrable liposomes formulations will be known or apparent to those skilled in the art and are described in detail in, for example, Remington's Pharmaceutical Science, 17th ed., Mack Publishing Company, Easton, PA (1985), and Gregoriadis (1988), supra .
  • the dose and the route of administration and the carrier used may vary based on the disease being treated and in view of known treatments for such diseases. Amounts effective for a particular use will depend on the severity of the disease and the weight and general state of the patient being treated. It must be kept in Mind that the materials of the present invention may be employed in serious disease states, that is, life-threatening or potentially life threatening situations. In such cases, in view of the ability of the liposomes to target the blood-brain barrier and the minimal immunogenicity of the antibody binding fragments, it is possible and may be felt desirable by the treating physician to administer substantial excesses of these compositions.
  • This Example describes the production of Fab'-coupled immunoliposomes for targeting to the transferrin receptor.
  • Liposomes were prepared with a Heat Systems W 380 cup horn sonicator (Farmington, NY) by a method modified from Barrow and Lentz, Biochim. Biophys. Acta, 597:92-99 (1980).
  • L-a-Phosphatidylcholine (PC) and N-[4-p-malimido phenyl butyryl] dioleoyl phosphatidylethanolamine (MPB-PE) were obtained from Avanti Polar Lipids, Inc. (Pelham, AL), and cholesterol (Chol) was purchased from Sigma Chemical Co. (St. Louis, MO).
  • Lipid films were dispersed in 0.9% (w/v) saline (or Hopes-buffered 0.9% saline), transferred to 10 ml polycarbonate test tubes in 1-2 ml aliquots, and sonicated continuously at 50°C for 2-3 min to visual clarity. Liposomes were checked for diameter site by filtration through 0.45 micron-diameter cellulose acetate filters (Millipore, Boston, MA).
  • F(ab') 2 fragments were prepared from "OX-26" anti-transferrin receptor monoclonal antibody (purchased from Bioproducts for Science, Inc. (Indianapolis, IN) by Loftrand Lab LTD (Gaithersburg, MD).
  • Nonspecific rabbit IgG F(ab') 2 was purchased from Organon Teknika-Cappel (Durham, NC).
  • Fab' fragments were generated from OX-26 F(ab') 2 (10 mg/ml) and nonspecific rabbit F(ab') 2 fragments (10 mg/ml) by reduction with 20 mM DTT (Sigma) in 20 mM HEPES (pH 6.5) for 60 min.
  • Fab' fragments were separated from excess DTT on minicolumns of Sephadex G-25 (Pharmacia Fine Chemicals, Uppsala, Sweden), made from the barrels of 3-ml plastic syringes according to the technique of Fry et al., Anal. Biochem. 90:809-815 (1987).
  • One-half ml aliquots of reduced Fab' were placed on previously centrifuged minicolumns and centrifuged at 1000 rpm for 10 min. The degree of reduction was determined by the method of Ellman, Arch. Biochem. Biophys. 82:70-77 (1959).
  • Fab'-coupled liposomes were isolated from the reaction mixture by flotation on a metrizamide (Sigma) gradient by the method of Heath et al., Biochim. Biophys. Acta 640:66-81 (1981). Briefly, 1 ml of liposomal suspension was mixed with 1 ml of 1 M metrizamide solution in 0.9% saline in a 5 ml nitrocellulose centrifuge tube. This solution was gently overlaid with 3 ml of 0.3 M metrizamide in 0.9% saline and topped with 0.5 ml of 0.9% saline.
  • the solution was centrifuged at 40,000 rpm for 1 h in a L8-80M ultracentrifuge (Beckman Instruments, Palo Alto, CA).
  • the liposomes were pipetted off the gradient, and the metrizamide was removed on a Sephadex G-25 minicolumn as previously described.
  • the protein concentrations of OX-26 anti-transferrin IgG Fab', and of nonspecific rabbit IgG Fab' (control) associated with the related liposomal formulations were estimated colorimetrically (Sigma Protein Assay Kit) to be 60 and 140 ⁇ g/ml, respectively.
  • Fab'-coupled liposomal formulations were not tested for receptor site binding. However, conjugates prepared from SATA-modified proteins have been shown to retain enzyme activity or function (Duncan et al., Anal. Biochem. 132:68-73 (1983)).
  • Intraarterial liposomal administration was undertaken to maximize liposome delivery and binding to the ipsilateral cerebral vasculature.
  • the advantage of this administration route occurs only during the initial passage of liposomes through ipsilateral brain. Liposomes then enter the systemic circulation and show pharmacokinetic behavior similar to liposomes administered intravenously (Greig, N. in Implications of the Blood-Brain Barrier and its Manipulation , vol. 1: "Basic Science Aspects,” (Neuwelt, E., ed.), pp. 311-368, Plenum Press, New York, NY (1989).
  • Liposomal formulations containing trace levels (0.5 ⁇ Ci/ml) of 14 C]-labeled DPPC were administered by infusion into the carotid artery catheter at a rate of 0.2 ml/min for 5 min (infusion pump No. 944, Harvard Instruments, Millis, MA).
  • the carotid bifurcation was observed to ensure that the infusate passed cephalad into the internal carotid artery and not in a retrograde fashion down the common carotid artery.
  • a pressure transducer Statham Instruments, Oxnard, CA
  • the rats were killed by decapitation, and brain, kidneys, liver, and spleen were removed from each animal and were weighed. Plasma, brain (cerebrum ipsilateral and contralateral to infusion site, and cerebellum), other organ samples, and aliquots of liposomal formulations were measured for radioactivity (Tri-Carb 2200 CA Liquid Scintillation Analyzer, Packard Instruments, Downers Grove, IL) according to the technique of Greig et al., J. Pharmacol. Exp. Ther. 245:1-7 (1988).
  • Radioactivity in organ samples was calculated as mean DPM/total DPM injected. Volumes of distribution (V d ) for [ 14 C]-DPPC-labeled liposomal formulations were calculated as follows: V d -DPM per gram wet tissue weight/DPM per ml plasma x 100 (% wet wt). In the calculation of radioactivity distributions, blood volume was assumed to be 6.5% of the total body weight (Altman, Blood and Other Body Fluids , Biological Handbook Series, Fed. Amer. Soc. Exp. Biol., Wash., D.C. (1961)). Tissue counts were corrected for counts present in residual blood (0.01 in brain, 0.1 in spleen, kidneys, and liver ( ibid .).
  • the liposomal diameter Assuming the liposomal diameter to be approximately 1000 ⁇ , the lipid bilayer thickness 37 ⁇ (Mason and Huang, Ann. N.Y. Acad. Sci. 308:29-48 (1978)), and the lipid (liposomal) density 0.9 g/cm 3 , the number of liposomes bound to the blood-brain barrier and the surface area occupied by bound liposomes were estimated. Capillary surface area in rat brain was estimated as 135 cm 2 /g wet weight brain (Altman, supra ).
  • V d values radioactivity per g wet weight of each organ divided by radioactivity per ml of plasma, normalize variability in plasma pharmacokinetics and liposomal plasma clearances among rats.
  • the V d values of the liposomal formulations (Table II) for OX-26 in brain were significantly greater than their respective controls at both 1 and 10 min, by approximately 2-fold at 1 min and by 6-8-fold at 10 min (p ⁇ 0.05, Dunnett's test). Although the V d value for right cerebrum was up to 3.5 fold greater than left cerebrum, this did not reach statistical significance (paired t-test). At 1 and 10 min, high levels of OX-26 liposomes were present in liver and spleen, indicating liposomal accumulation in these organs. V d values of all formulations in brain tissue did not increase between 1 and 10 min, indicating that liposomes did not measurably cross the blood-brain barrier.
  • OX-26 liposomal brain uptake remained constant rather than increasing after 1 min, suggesting that essentially all the receptor sites were occupied after 1 min. This result is consistent with the observation that OX-26 antibodies show significant binding to capillaries at 5 min after injection (Friden et al., Proc. Natl. Acad. Sci. USA 88:4771-4775 (1991)). No increased brain liposomal uptake was observed during the brief 10 min period used in this study.
  • the capillary surface area in rat brain cortex is about 135 cm 2 per gram of brain (wet wt), or 230 cm 2 for rats in the present study; therefore, it was estimated that about 0.7% of brain capillary surface was covered with liposomes.
  • Liposomal binding to brain can be increased to cover all of the capillary surface by upregulating the transferrin receptor or targeting other receptors, e.g., in a 270 g rat as used in this study, this would represent 3.8 pmol of liposomal brain uptake.
  • OX-26 Fab'-coupled liposomes showed significant liver and spleen uptakes at 1 and 10 min after infusion.
  • OX-26 liposomes demonstrated an unusually high spleen uptake, with 6% of their total radioactivity present in the spleen after 1 min, and 12% after 10 min. This enhanced uptake is likely due to the many transferrin receptors in spleen or on red blood cells, which are rapidly cleared by the spleen after binding to OX-26 liposomes. This suggests that OX-26 liposomes can be used to effectively target therapeutic agents to the spleen.
  • This Example compares the ability of insulin-targeted liposomes to distribute labeled formulations in brain when compared to control preparations. Although the brain distribution of insulin-coupled liposomes was not statistically different from the control formulations, V d values, which adjust data for plasma clearance, were higher for insulin liposomes in right cerebrum than controls at 1 and 10 min, suggesting that a moderate binding to brain capillaries does occur.
  • the [ 14 C]-DPPC-labeled liposomal formulations evaluated in this study consisted of 8 ⁇ mol/ml suspensions of PC/Chol/MPB-PE lipids (molar ratio, 10/5/1), covalently coupled to proteins.
  • the protein concentrations of insulin, of OX-26 anti-transferrin IgG Fab', and of nonspecific rabbit IgG Fab' (control) associated with the related liposomal formulations were estimated colorimetrically (Sigma Protein Assay Kit) to be 250, 60 and 140 ⁇ g/ml, respectively.
  • Insulin (porcine, sodium) and N-succinimidyl-S-acetyl-thioacetate (SATA) and were obtained from Cal Biochem Corp. (LaJolla, CA). Insulin was thiolated with SATA by a modification of the method of Duncan et al., Anal. Biochem 132:68-73 (1983). Twenty ⁇ l of SATA in dimethyl formamide (DMF) (100 mg/ml) was reacted per 1 ml of insulin solution (10 mg/ml insulin + 5 ⁇ l 5 N NaOH) in deionized water for 30 min.
  • DMF dimethyl formamide
  • Thioacetylated insulin was deacetylated by reaction with 100 ⁇ l (per ml insulin solution) of aqueous 0.5 M hydroxylamine (pH 6.8) for 30 min. Thiolated insulin was separated from low molecular weight solutes on minicolumns of Sephadex® G-25, made from the barrels of 3-ml plastic syringes according to the technique of Fry et al., Anal. Biochem. 90:809-815 (1978). One-half ml aliquots of thiolated insulin solution were placed on previously centrifuged minicolumns and centrifuged at 1,000 rpm for 10 min. After addition of 0.2 ml of saline, this centrifugation stop was repeated. The extent of thiolation was determined by the method of Ellman, supra .
  • Freshly thiolated insulin was added to an equivalent volume of freshly prepared liposomes (in 20 mM Hepes-buffered saline, pH 7.5) and mechanically stirred at room temperature overnight. Insulin-coupled liposomes were isolated from the reaction mixture by flotation on a metrizamide gradient as described in Example I above.
  • the protein concentration of insulin associated with the liposomal formulation was estimated colorimetrically to be 250 ⁇ g/ml. Insulin-coupled liposomal formulations were not tested for receptor site binding. However, conjugates prepared from SATA-modified proteins have been shown to retain enzyme activity or function (Duncan et al., supra ).
  • V d values of insulin liposomes in right cerebrum were significantly higher than control values at 1 and 10 min by approximately 2-fold (P ⁇ 0.05, Dunnett's test). Values in left cerebrum, however, were not different from controls, nor were there left-right differences in cerebrum V d values.
  • a liposome is prepared according to Example I, incorporating a transportable neuropeptide to be targeted to the brain of an animal.
  • a monoclonal antibody to human insulin receptor is digested to prepare Fab' fragments which are coupled to the liposome as described in Example I.
  • the resulting targeting immunoliposome is combined with sterile saline to provide a physiologically acceptable solution, and is administered to the patient or subject parenterally.
  • a liposome is prepared according to Example I, incorporating a pharmacological compound to be targeted for delivery to the brain of a patient or subject.
  • a monoclonal antibody to human IGF-I receptor is digested as described in Example I to prepare Fab' fragments.
  • the Fab' fragment are coupled to the liposome as described in Example I.
  • the resulting targeting immunoliposome is combined with sterile saline to provide a physiologically acceptable solution, and is administered to the patient or subject parenterally.
  • the subject invention provides antibody binding fragment-targeted liposomal formulations useful in the delivery of therapeutics and diagnostic compounds across the blood-brain barrier.
  • the presence of antibody binding fragments in a liposome which are specific for brain transport receptor, such as transferrin receptor, insulin receptor, IGF-I or IGF-II receptor provides an effective means to enhance the uptake of certain drugs, such as hydrophilic drugs, peptides and proteins to the brain.
  • the antibody binding fragment-modified liposomal formulations may be produced by a variety of means.
  • increased efficacy, convenience and economics of lower dosages and less frequent administration to achieve therapeutic levels of drugs in the brain are among the advantages provided by compositions of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (20)

  1. Composition qui comprend un liposome couplé à un fragment liant d'anticorps qui se lie à une molécule de récepteur présente sur les cellules endothéliales vasculaires de la barrière hémato-encéphalique d'un mammifère.
  2. Composition de la Revendication 1, dans laquelle le fragment liant d'anticorps est un fragment Fab, F(ab')2, Fab' ou un polypeptide de chaíne d'anticorps unique.
  3. Composition selon la Revendication 1, dans laquelle le fragment d'anticorps se lie à un récepteur du système de transport des peptides cérébraux.
  4. Composition selon la Revendication 3, dans laquelle le récepteur est le récepteur de la transferrine, le récepteur de l'insuline, le récepteur de l'IGF-1 ou de l'IGF-2.
  5. Composition selon la Revendication 1, dans laquelle le fragment liant d'anticorps est couplé au liposome par une liaison covalente.
  6. Composition selon la Revendication 1, dans laquelle le liposome contient un composé pharmaceutique.
  7. Composition de la Revendication 6, dans laquelle le composé pharmacologique est un neuropeptide hydrophile.
  8. Composition selon la Revendication 6, comprenant en outre un support physiologiquement acceptable.
  9. Composition selon la Revendication 1, dans laquelle le diamètre du liposome est inférieur à 1 micron.
  10. Composition selon la Revendication 9, dans laquelle le diamètre du liposome est inférieur à environ 0,45 micron.
  11. Composition de la Revendication 1, dans laquelle le fragment liant d'anticorps est un fragment Fab, F(ab')2 ou Fab' qui se lie spécifiquement au récepteur de la transferrine.
  12. Composition de la Revendication 1, dans laquelle le fragment liant d'anticorps est préparé à partir d'un anticorps monoclonal.
  13. Composition pharmaceutique qui comprend un fragment liant d'anticorps qui se lie à une molécule de récepteur présente sur les cellules endothéliales vasculaires de la barrière hémato-encéphalique d'un mammifère, dans laquelle le fragment liant d'anticorps est couplé à un liposome qui contient un composé pharmaceutique destiné au traitement d'un trouble en rapport avec le cerveau, et un support pharmaceutiquement acceptable.
  14. Composition pharmaceutique de la Revendication 13, dans laquelle le fragment liant d'anticorps est un fragment Fab, F(ab')2, Fab' ou un polypeptide de chaíne d'anticorps unique.
  15. Composition pharmaceutique de la Revendication 14, dans laquelle le récepteur est le récepteur de la transferrine, le récepteur de l'insuline, le récepteur de l'IGF-I ou de l'IGF-2.
  16. Utilisation d'une composition qui comprend un liposome contenant un composé pharmacologique couplé à un fragment liant d'anticorps qui se lie à une molécule de récepteur présente sur les cellules endothéliales vasculaires de la barrière hémato-encéphalique d'un mammifère, pour la fabrication d'un médicament permettant le ciblage dudit composé pharmacologique pour sa délivrance à la barrière hémato-encéphalique dudit mammifère.
  17. Utilisation d'une composition selon la Revendication 16, dans laquelle la composition est à administrer par voie intraveineuse ou intra-artérielle.
  18. Utilisation d'une composition selon la Revendication 16, dans laquelle le fragment liant d'anticorps se lie spécifiquement au récepteur de la transterrine, au récepteur de l'insuline, au récepteur de l'IGF-I ou de l'IGF-2.
  19. Utilisation d'une composition selon la Revendication 16, dans laquelle le fragment liant d'anticorps est un fragment Fab, F(ab')2, Fab' ou un polypeptide de chaíne d'anticorps unique.
  20. Utilisation d'une composition selon la Revendication 16, dans laquelle le récepteur est le récepteur de la transferrine.
EP93917326A 1992-07-27 1993-07-23 Ciblage de liposomes sur la barriere hemato-encephalique Expired - Lifetime EP0652775B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92119992A 1992-07-27 1992-07-27
US921199 1992-07-27
PCT/US1993/006942 WO1994002178A1 (fr) 1992-07-27 1993-07-23 Ciblage de liposomes sur la barriere hemato-encephalique

Publications (2)

Publication Number Publication Date
EP0652775A1 EP0652775A1 (fr) 1995-05-17
EP0652775B1 true EP0652775B1 (fr) 2000-04-19

Family

ID=25445079

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93917326A Expired - Lifetime EP0652775B1 (fr) 1992-07-27 1993-07-23 Ciblage de liposomes sur la barriere hemato-encephalique

Country Status (8)

Country Link
US (1) US20020025313A1 (fr)
EP (1) EP0652775B1 (fr)
JP (1) JPH07509250A (fr)
AT (1) ATE191853T1 (fr)
AU (1) AU677216B2 (fr)
CA (1) CA2141216A1 (fr)
DE (1) DE69328430T2 (fr)
WO (1) WO1994002178A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118376A1 (fr) 2011-03-01 2012-09-07 To-Bbb Holding B.V. Chargement liposomal actif avancé de substances médiocrement solubles dans l'eau

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
WO1996026745A1 (fr) * 1995-02-28 1996-09-06 Nature Technology Corporation Vecteurs de virus biosynthetiques a usage en therapie genique
JP4512882B2 (ja) * 1996-02-09 2010-07-28 チェング ピー―ワン 受容体リガンドにより促進される生物活性分子の送達
AU6443298A (en) 1997-02-28 1998-09-18 Nature Technology Corporation Self-assembling genes, vectors and uses thereof
WO1999000150A2 (fr) * 1997-06-27 1999-01-07 Regents Of The University Of California Ciblage d'un medicament radiopharmaceutique peptidique utilisant in vivo la barriere hemato-encephalique d'un primate et un anticorps monoclonal dirige contre le recepteur humain de l'insuline
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
WO2003084469A2 (fr) * 2002-04-01 2003-10-16 Utah Ventures Ii, L.P. Proteines de membranes endotheliales specifiques de tissus
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20060057192A1 (en) * 2001-09-28 2006-03-16 Kane Patrick D Localized non-invasive biological modulation system
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
US20070065497A1 (en) * 2005-09-20 2007-03-22 Guilford Frederick T Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050142141A1 (en) * 2002-11-27 2005-06-30 Pardridge William M. Delivery of enzymes to the brain
US7592143B2 (en) * 2003-04-18 2009-09-22 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
CN1938428A (zh) 2003-11-12 2007-03-28 先灵公司 多基因表达的质粒系统
PE20050928A1 (es) * 2003-11-21 2005-11-08 Schering Corp Combinaciones terapeuticas de anticuerpo anti-igfr1
CN1922313B (zh) 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US8349359B2 (en) * 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
ATE493442T1 (de) * 2004-12-03 2011-01-15 Schering Corp Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
CA2900876A1 (fr) 2004-12-22 2006-08-17 Bhi Limited Partnership Methodes et compositions de traitement de maladies liees a l'amyloide
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
EP2279726A3 (fr) 2005-05-26 2012-06-20 Biorest Ltd. Compositions et méthodes d'utilisation desdites compositions dans l'administration d'agents dans un organe cible protégé par une barrière sanguine
AU2006259536A1 (en) * 2005-06-15 2006-12-28 Schering Corporation Anti-IGF1R antibody formulations
WO2007120334A2 (fr) 2005-12-15 2007-10-25 Genentech, Inc. Méthodes et compositions de ciblage de la polyubiquitine
MY165105A (en) 2006-07-14 2018-02-28 Ac Immune Sa Humanized antibody against amyloid beta
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
EP2170389B1 (fr) 2007-06-12 2014-10-29 AC Immune S.A. Anticorps humanisés anti-beta amyloïde
TWI453217B (zh) 2007-06-12 2014-09-21 Ac Immune Sa 抗β類澱粉蛋白單株抗體
US20090047318A1 (en) * 2007-08-16 2009-02-19 Abbott Cardiovascular Systems Inc. Nanoparticle-coated medical devices and formulations for treating vascular disease
EP2650308A3 (fr) 2007-10-05 2014-11-12 Genentech, Inc. Utilisation d'anticorps anti-beta amyloide aux maladies oculaires
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
US20110223147A1 (en) 2008-05-07 2011-09-15 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US8680020B2 (en) 2008-07-15 2014-03-25 Academia Sinica Glycan arrays on PTFE-like aluminum coated glass slides and related methods
CA2736729A1 (fr) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Beta-peptides amyloides et procedes d'utilisation associes
KR20190025057A (ko) 2008-10-14 2019-03-08 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
CA2741089A1 (fr) 2008-10-22 2010-04-29 Genentech, Inc. Modulation de la degenerescence d'axons
US20120009182A1 (en) 2008-12-23 2012-01-12 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
WO2011005098A1 (fr) 2009-07-10 2011-01-13 Abbott Healthcare Products B.V. Peptides ligands permettant de cibler la barrière sang cerveau
WO2011028950A1 (fr) 2009-09-02 2011-03-10 Genentech, Inc. Mutant smoothened et ses méthodes d'utilisation
RU2012120783A (ru) 2009-10-22 2013-11-27 Женентек, Инк. Модуляция дегенерации аксона
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
BR112012014022A2 (pt) 2009-12-11 2017-04-04 Genecode As composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico
TWI505836B (zh) 2009-12-11 2015-11-01 Genentech Inc 抗－ｖｅｇｆ－ｃ抗體及其使用方法
US8771685B2 (en) 2009-12-23 2014-07-08 F. Hoffmann-La Roche Ag Anti-BV8 antibodies and uses thereof
WO2011130332A1 (fr) 2010-04-12 2011-10-20 Academia Sinica Puces au glycane pour la recherche par criblage haut débit de virus
WO2011143262A2 (fr) 2010-05-10 2011-11-17 Sinica, Academia Congénères de phosphonate de zanamivir ayant une activité antigrippale et détermination de la sensibilité à l'oseltamivir d'influenzavirus
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
WO2012020124A1 (fr) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccin obtenu par génie génétique
EP2625197B1 (fr) 2010-10-05 2016-06-29 Genentech, Inc. Mutant smoothened et ses procédés d'utilisation
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
AU2011322553B2 (en) 2010-10-26 2015-07-02 Ac Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
MX346500B (es) 2010-11-10 2017-03-22 Genentech Inc * Metodos y composiciones para inmunoterapia para enfermedad neural.
SI2646470T1 (sl) 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
EP3345627B1 (fr) 2011-06-03 2021-01-06 Ophidion Inc. Compositions et procédés de transport à travers la barrière hémato-encéphalique
EP2739304A4 (fr) * 2011-08-04 2015-06-03 Univ Ramot Particules destinées au traitement de maladies neurodégénératives
MX354662B (es) 2011-10-07 2018-03-14 Ac Immune Sa Anticuerpos fosfoespecificos que reconocen la tau.
CN103974709B (zh) 2011-10-14 2016-12-14 霍夫曼-拉罗奇有限公司 Bace1的肽抑制剂
BR112014011127A2 (pt) 2011-11-10 2017-05-16 Genentech Inc métodos para tratar, diagnosticar e monitorar doença de alzheimer
AU2013243861A1 (en) 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013177062A2 (fr) 2012-05-21 2013-11-28 Genentech, Inc. Procédés pour améliorer la sécurité du transport à travers la barrière hémato-encéphalique
RU2014148732A (ru) 2012-05-22 2016-07-20 Ф. Хоффманн-Ля Рош Аг Замещенные дипиридиламины и их применение
PE20150400A1 (es) 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CA2878478A1 (fr) 2012-07-06 2014-01-09 Genentech, Inc. Benzamides n-substitues et leurs procedes d'utilisation
AU2013306098A1 (en) 2012-08-18 2015-02-12 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
CA2883168A1 (fr) 2012-08-21 2014-02-27 Academia Sinica Composes benzocyclo-octyne et leurs utilisations
RU2015113746A (ru) 2012-09-27 2016-11-20 Ф. Хоффманн-Ля Рош Аг Замещенные сульфонамиды
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
CN104918934B (zh) 2013-01-18 2017-12-22 霍夫曼-拉罗奇有限公司 3‑取代的吡唑及其作为dlk抑制剂的用途
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
JP6096370B2 (ja) 2013-03-14 2017-03-15 ジェネンテック， インコーポレイテッド 置換トリアゾロピリジンとその使用方法
MX374811B (es) 2013-03-15 2025-03-06 Ac Immune Sa Anticuerpos anti-tau y métodos de uso.
KR20160002850A (ko) 2013-05-01 2016-01-08 에프. 호프만-라 로슈 아게 C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도
MX2015015130A (es) 2013-05-01 2016-02-18 Hoffmann La Roche Compuestos de biheteroarilo y usos de los mismos.
JP6612214B2 (ja) 2013-05-20 2019-11-27 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及び使用方法
WO2014210397A1 (fr) 2013-06-26 2014-12-31 Academia Sinica Antigènes rm2 et leur utilisation
WO2014210564A1 (fr) 2013-06-27 2014-12-31 Academia Sinica Conjugués de glycane et leur utilisation
JP2016529284A (ja) 2013-08-27 2016-09-23 ノースイースタン ユニバーシティ ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
CA2923579C (fr) 2013-09-06 2023-09-05 Academia Sinica Activation des cellules humaines inkt a l'aide de glycolipides ayant des groupes glycolsyles modifies
AR097661A1 (es) 2013-09-17 2016-04-06 Obi Pharma Inc Composiciones de una vacuna de carbohidratos para inducir respuestas inmunológicas y sus usos en el tratamiento del cáncer
MX363457B (es) 2013-10-11 2019-03-25 Hoffmann La Roche Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
MX2016008110A (es) 2013-12-20 2016-08-19 Hoffmann La Roche Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
EP3087193A4 (fr) * 2013-12-27 2017-08-09 Teloregen, Inc. Compositions et procédés permettant de fournir de la télomérase active à des cellules in vivo
WO2016114819A1 (fr) 2015-01-16 2016-07-21 Academia Sinica Compositions et méthodes pour traiter et détecter des cancers
EP3094352B1 (fr) 2014-01-16 2020-09-23 Academia Sinica Compositions et méthodes pour traiter et détecter des cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
WO2015120075A2 (fr) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened et méthodes d'utilisation de celui-ci
WO2015148915A1 (fr) 2014-03-27 2015-10-01 Academia Sinica Composés de marquage réactifs et leurs utilisations
JP7062361B2 (ja) 2014-05-27 2022-05-06 アカデミア シニカ 抗ｈｅｒ２糖操作抗体群およびその使用
EP3149161B1 (fr) 2014-05-27 2021-07-28 Academia Sinica Fucosidase issue de bacteroïdes et ses procédés d'utilisation
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
KR20240096599A (ko) 2014-05-27 2024-06-26 아카데미아 시니카 항-ｃｄ20 글리코항체 및 이의 용도
WO2015184001A1 (fr) 2014-05-28 2015-12-03 Academia Sinica Glycoanticorps anti-thf-alpha et leurs utilisations
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
AU2015315294B2 (en) 2014-09-08 2020-09-17 Academia Sinica Human iNKT cell activation using glycolipids
US10160799B2 (en) 2014-11-19 2018-12-25 Axon Neuroscience Se Humanized tau antibodies in a alzheimer's disease
WO2016081640A1 (fr) 2014-11-19 2016-05-26 Genentech, Inc. Anticorps multispécifiques anti-récepteur de la transferrine/anti-bace1 et leurs procédés d'utilisation
JP6779876B2 (ja) 2014-11-19 2020-11-04 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体抗体及びその使用方法
CN107108745B (zh) 2014-11-19 2021-01-12 基因泰克公司 抗bace1的抗体和其用于神经疾病免疫疗法的用途
CN107207591A (zh) 2014-12-10 2017-09-26 豪夫迈·罗氏有限公司 血脑屏障受体抗体及使用方法
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
KR102691114B1 (ko) 2015-01-24 2024-08-01 아카데미아 시니카 신규한 글리칸 콘주게이트 및 이를 사용하는 방법
WO2016118961A1 (fr) 2015-01-24 2016-07-28 Academia Sinica Marqueurs de cancer et leurs procédés d'utilisation
CN107614521B (zh) 2015-01-30 2022-02-08 台湾地区“中央研究院” 增进抗体功效的通用糖型组合物及方法
HK1244512A1 (zh) 2015-02-04 2018-08-10 健泰科生物技术公司 突变型smoothened及其使用方法
EP3268373B1 (fr) 2015-03-09 2022-04-27 F. Hoffmann-La Roche AG Tricycliques inhibiteurs de dlk et leur utilisation
AU2016268120A1 (en) 2015-05-22 2017-11-30 Genentech, Inc. Substituted benzamides and methods of use thereof
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
HK1256912A1 (zh) 2015-09-04 2019-10-04 台湾浩鼎生技股份有限公司 聚糖阵列以及使用方法
KR20250007038A (ko) 2015-10-02 2025-01-13 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3380466A1 (fr) 2015-11-25 2018-10-03 Genentech, Inc. Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
AU2017213826A1 (en) 2016-02-04 2018-08-23 Curis, Inc. Mutant smoothened and methods of using the same
AU2017231749A1 (en) 2016-03-08 2018-09-20 Academia Sinica Methods for modular synthesis of N-glycans and arrays thereof
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
TWI780045B (zh) 2016-03-29 2022-10-11 台灣浩鼎生技股份有限公司 抗體、醫藥組合物及方法
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
RU2018140976A (ru) 2016-04-22 2020-05-22 Оби Фарма, Инк. Иммунотерапия рака путем иммунной активации или иммунной модуляции через антигены серии globo
EP3487853B1 (fr) 2016-07-20 2022-06-08 F. Hoffmann-La Roche AG Composés de proline bicycliques
JP6975515B2 (ja) 2016-07-20 2021-12-01 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Ｔｒｐａ１モデュレーターとしてのスルホニルシクロアルキルカルボキサミド化合物
US11642400B2 (en) 2016-07-27 2023-05-09 Obi Pharma, Inc. Immunogenic/therapeutic glycan compositions and uses thereof
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
EP3497093B1 (fr) 2016-08-12 2021-09-15 F. Hoffmann-La Roche AG Inhibiteurs de sulfonylpyridyle trp
CA3034057A1 (fr) 2016-08-22 2018-03-01 CHO Pharma Inc. Anticorps, fragments de liaison, et procedes d'utilisation
EP3526219B1 (fr) 2016-10-17 2021-12-15 F. Hoffmann-La Roche AG Lactames de pyridone bicycliques et leurs méthodes d'utilisation
KR20190077103A (ko) 2016-11-21 2019-07-02 오비아이 파머 인코퍼레이티드 접합된 생물학적 분자, 제약 조성물 및 방법
CN110225911B (zh) 2016-11-28 2022-04-05 豪夫迈·罗氏有限公司 噁二唑酮瞬时受体电位通道抑制剂
JP6890179B2 (ja) 2016-12-02 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式アミド化合物及びその使用方法
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
CN110461838B (zh) 2017-03-07 2022-05-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
WO2018175707A1 (fr) 2017-03-24 2018-09-27 Genentech, Inc. Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques
CN108939089B (zh) * 2017-05-17 2021-11-02 复旦大学 群体感应多肽及其在制备肿瘤靶向诊治递药系统中的用途
CN110997693A (zh) 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂
CA3067944C (fr) 2017-07-14 2023-03-14 F. Hoffmann-La Roche Ag Composes cetoniques bicycliques et leurs procedes d'utilisation
EP3668886A2 (fr) 2017-08-18 2020-06-24 Adrx, Inc. Inhibiteurs peptidiques d'agrégation de tau
JP7362600B2 (ja) 2017-10-11 2023-10-17 エフ． ホフマン－ラ ロシュ アーゲー Ｒｉｐ１キナーゼ阻害剤として使用するための二環式化合物
JP7438942B2 (ja) 2017-10-30 2024-02-27 エフ． ホフマン－ラ ロシュ アーゲー 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
CA3078688A1 (fr) 2017-10-31 2019-05-09 F. Hoffmann-La Roche Ag Sulfones et sulfoxydes bicycliques et procedes d'utilisation associes
MX2020005564A (es) 2017-11-30 2020-11-06 Hanmi Pharm Ind Co Ltd Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.
US10722465B1 (en) 2017-12-08 2020-07-28 Quicksilber Scientific, Inc. Transparent colloidal vitamin supplement
US11344497B1 (en) 2017-12-08 2022-05-31 Quicksilver Scientific, Inc. Mitochondrial performance enhancement nanoemulsion
WO2019164778A1 (fr) 2018-02-20 2019-08-29 Genentech, Inc. Procédé de préparation de composés antagonistes du canal potentiel de récepteur transitoire de 1-arylsulfonyl-pyrrolidine-2-carboxamide et formes cristallines associées
WO2019165290A1 (fr) 2018-02-26 2019-08-29 Genentech, Inc. Composés de pyridine-sulfonamide et leur utilisation contre la douleur et les états associés
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
KR20200144551A (ko) 2018-03-28 2020-12-29 악손 뉴로사이언스 에스이 알츠하이머병을 검출하고 치료하는 항체-기반 방법
WO2019191702A1 (fr) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Hydro-pyrido-azines substituées utilisées comme inhibiteurs du canal sodique
EP3781571B1 (fr) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG Dérivés de n-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide et composés similaires en tant qu'inhibiteurs de la kinase rip1 pour le traitement p.e. du syndrome de l'intestin irritable (sii)
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN112805267B (zh) 2018-09-03 2024-03-08 豪夫迈·罗氏有限公司 用作tead调节剂的甲酰胺和磺酰胺衍生物
EP3898667A2 (fr) 2018-12-20 2021-10-27 F. Hoffmann-La Roche AG Fc d'anticorps modifiés et méthodes d'utilisation
AR119673A1 (es) 2019-01-11 2022-01-05 Hoffmann La Roche Compuestos bicíclicos de cetona y métodos para utilizarlos
EP3946269A4 (fr) * 2019-03-27 2023-05-03 University of Georgia Research Foundation, Inc. Procédés de fabrication de vésicules ciblées, et compositions ainsi fabriquées
US11291702B1 (en) 2019-04-15 2022-04-05 Quicksilver Scientific, Inc. Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
KR20220101138A (ko) 2019-11-13 2022-07-19 제넨테크, 인크. 치료적 화합물 및 사용 방법
US20250340623A1 (en) 2019-12-04 2025-11-06 Ac Immune Sa Novel Molecules for Therapy and Diagnosis
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
WO2022034228A1 (fr) 2020-08-14 2022-02-17 Ac Immune Sa Molécules de liaison anti-tdp-43 humanisées et leurs utilisations
EP4222154A1 (fr) 2020-10-02 2023-08-09 Genentech, Inc. Procédé de préparation de composés bihétéroaryle et leurs formes cristallines
WO2022079297A1 (fr) 2020-10-16 2022-04-21 Ac Immune Sa Anticorps se liant à l'alpha-synucléine à usage thérapeutique et diagnostique
WO2023028056A1 (fr) 2021-08-24 2023-03-02 Genentech, Inc. 3-amino pipéridyle utilisée en tant qu'inhibiteurs de canaux sodiques
WO2023028077A1 (fr) 2021-08-24 2023-03-02 Genentech, Inc. Inhibiteurs de canaux sodiques et leurs procédés de conception
JP2024543912A (ja) 2021-11-24 2024-11-26 ジェネンテック， インコーポレイテッド 二環式治療用化合物及びがんの処置における使用方法
WO2023097195A1 (fr) 2021-11-24 2023-06-01 Genentech, Inc. Composés d'indazole thérapeutiques et méthodes d'utilisation dans le traitement du cancer
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023171009A1 (fr) 2022-03-09 2023-09-14 株式会社Cured Anticorps humanisé qui se lie à une protéine eva1 ou fragment fonctionnel de celui-ci, conjugué anticorps-médicament et récepteur antigénique chimérique
CN119156401A (zh) 2022-04-08 2024-12-17 Ac免疫有限公司 抗tdp-43结合分子
JP2025535115A (ja) 2022-10-11 2025-10-22 メイラグティーエックス ユーケー アイアイ リミティド Ｕｐｆ１発現構築物
WO2024184494A1 (fr) 2023-03-08 2024-09-12 Ac Immune Sa Molécules de liaison anti-tdp-43 et leurs utilisations
AU2024322991A1 (en) 2023-08-09 2026-01-08 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof
WO2026013218A1 (fr) 2024-07-10 2026-01-15 Ac Immune Sa Vecteurs anti-tdp-43, molécules de liaison et leurs utilisations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010819A1 (fr) * 1991-11-26 1993-06-10 Alkermes, Inc. Procede de preparation de conjugues d'agents diagnostiques ou neuropharmaceutiques-anticorps specifiques de recepteur de transferine
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
CA2025907A1 (fr) * 1989-09-21 1991-03-22 Franklin D. Collins Methode pour le transport de composes a travers la barriere hemato-encephalique
AU8007791A (en) * 1990-06-15 1992-01-07 Cytel Corporation Intercellular adhesion mediators
CA2072249C (fr) * 1991-06-28 2003-06-17 Saiko Hosokawa Anticorps monoclonal humain liant specifiquement a la surface d'un antigene des membranes des cellules cancereuses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICKLUS ET AL, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1124, 1992, pages 7 - 12 *
NEUWELT ET AL: "DELIVERY OF MELANOMA ASSOCIATED IMMUNOGLOBULIN ANTIBODY AND FAB FRAGMENTS TO NORMAL BRAIN UTILIZING OSMOTIC BLOOD BRAIN BARRIER DISRUPTION", CANCER RESEARCH, vol. 48, 1988, pages 4725 - 4729, XP008072220 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012118376A1 (fr) 2011-03-01 2012-09-07 To-Bbb Holding B.V. Chargement liposomal actif avancé de substances médiocrement solubles dans l'eau

Also Published As

Publication number Publication date
DE69328430D1 (de) 2000-05-25
JPH07509250A (ja) 1995-10-12
EP0652775A1 (fr) 1995-05-17
AU4687593A (en) 1994-02-14
US20020025313A1 (en) 2002-02-28
WO1994002178A1 (fr) 1994-02-03
CA2141216A1 (fr) 1994-02-03
AU677216B2 (en) 1997-04-17
ATE191853T1 (de) 2000-05-15
DE69328430T2 (de) 2001-01-25

Similar Documents

Publication Publication Date Title
EP0652775B1 (fr) Ciblage de liposomes sur la barriere hemato-encephalique
US6660525B2 (en) Therapeutic liposome composition and method
Allen et al. Antibody-mediated targeting of long-circulating (StealthR) liposomes
US6027726A (en) Glycosylated protein-liposome conjugates and methods for their preparation
CA2067178C (fr) Methode et composition pour le traitement des tumeurs solides
EP0912198B1 (fr) Immunoliposomes optimisant l'internalisation dans des cellules cibles
US7220833B2 (en) Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
Torchilin et al. Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium
AU2002305094B2 (en) Liposome composition for improved intracellular delivery of a therapeutic agent
Vingerhoeds et al. Immunoliposomes in vivo
US5780054A (en) Methods for increasing the circulation half-life of protein-based therapeutics
US5366958A (en) Localized delivery using fibronectin conjugates
CA2605560A1 (fr) Composition d'immunoliposomes destinee au ciblage d'un recepteur des cellules her2
JP2001510451A (ja) 弱塩基性薬物を担持するイオン運搬体―中介リポゾーム
Emanuel et al. Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes
US20030008014A1 (en) Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells
Konno et al. Antitumor effect of adriamycin entrapped in liposomes conjugated with anti-human α-fetoprotein monoclonal antibody
WO1999059643A2 (fr) Complexe d'apport par liposomes
WO1998022092A1 (fr) Transport de liposomes a travers la barriere hemato-encephalique
WO2003105765A2 (fr) Micelles phospholipidiques dans des liposomes, servant d'agents de solubilisation pour des composes insolubles dans l'eau
Micklus et al. Targeting of Liposomes to the Blood-Brain Barrier in Rats
Klibanov Antibody-mediated targeting of PEG-coated liposomes
Spanjer Targeting of liposomes to liver cells in vivo.
WO2007133627A2 (fr) Procédé de fabrication de conjugués de liposomes avec des ligands sensibles à la température

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950201

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19960118

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000419

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000419

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20000419

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000419

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000419

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000419

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000419

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000419

REF Corresponds to:

Ref document number: 191853

Country of ref document: AT

Date of ref document: 20000515

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69328430

Country of ref document: DE

Date of ref document: 20000525

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000719

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000719

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20000719

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000723

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 20000731

ET Fr: translation filed
NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20090728

Year of fee payment: 17

Ref country code: FR

Payment date: 20090717

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090727

Year of fee payment: 17

Ref country code: DE

Payment date: 20090729

Year of fee payment: 17

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100723

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110331

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110201

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69328430

Country of ref document: DE

Effective date: 20110201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100802

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100723

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100723